A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects with Myelofibrosis

ID Number 11-0969

Principal Investigator(s)
Ronald Hoffman

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to determine the safety, tolerability, maximum tolerated dose or clinically active dose of a new investigational (experimental) drug, BMS-911543, in subjects with myelofibrosis (MF).

You may qualify to take part in this research study because you have myelofibrosis.

BMS-911543 is an investigational drug that has been designed to block a gene mutation (change or alteration in the structure of the gene) in a specific human protein, called Janus Kinase 2 (JAK2), which is known to be important in cancer cell growth in subjects with MF. This protein is part of a messaging system inside the bone-producing cells (known as stem cells) in the bone marrow. The JAK2 mutation causes the messaging system to malfunction resulting in the stem cells producing too many blood cells.  About half of the subjects with MF have the JAK2 mutation. It is not entirely certain whether the drug will affect cells that do not contain mutated JAK2 proteins. Therefore, it is possible that even people that do not express any mutation on any of their cells may experience side effects that might be due to the drug.

Contact Information
Jill Kleczko
(212) 241-0573

Recruiting Patients: No